Bremelanotide

Bremelanotide (PT-141) was discovered as an active metabolite of Melanotan II during clinical testing, then developed by Palatin Technologies as a treatment for female sexual dysfunction. What it is: It is a cyclic synthetic peptide analog of alpha-MSH, lacking the amide C-terminus of Melanotan II. It falls under Anti-aging/Cosmetic (brand name Vyleesi). Proposed Mechanisms & Research Findings: It acts as a melanocortin receptor agonist, primarily targeting MC3R and MC4R in the central nervous system to modulate sexual response pathways. Regulatory & Safety Status: It is FDA approved (2019) for hypoactive sexual desire disorder in premenopausal women. Sourcing from unauthorized clinics or websites is unsafe. Athletic & Anti-Doping Status: Strictly prohibited by WADA under Section S2 as a melanocortin agonist.